Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
View Patent ↗The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express a hepatic stellate phenotype and cells that express a hepatic sinusoidal endothelial phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of liver deficiency, liver metabolism studies, and liver toxicity studies.
1. A method for producing cells with a hepatic stellate phenotype and cells with a hepatic sinusoidal endothelial phenotype, comprising:
(a) culturing pluripotent cells with about 5 ng/ml to about 500 ng/ml Wnt3a and about 10 ng/ml to about 1,000 ng/ml ActivinA;
(b) then culturing the cells of step (a) with about 1 ng/ml to about 100 ng/ml bFGF and about 5 ng/ml to about 500 ng/ml BMP4;
(c) then culturing the cells of step (b) with about 5 ng/ml to about 500 ng/ml aFGF, about 1 ng/ml to about 100 ng/ml FGP4 and about 2.5 ng/ml to about 250 ng/ml FGF8b;
(d) then culturing the cells of step (c) with about 2 ng/ml to about 200 ng/ml HGF and about 10 ng/ml to about 1,000 ng/ml Follistatin; and
(e) isolating hepatic stellate cells and/or hepatic endothelial sinusoidal cells produced by the differentiation protocol.
2. The method of claim 1 , wherein the cells are cultured in step (a) with about 50 ng/ml Wnt3a and about 100 ng/ml ActivinA.
3. The method of claim 1 , wherein the cells are cultured in step (b) with about 10 ng/ml bFGF and about 50 ng/ml BMP4.
4. The method of claim 1 , wherein the cells are cultured in step (c) with about 50 ng/ml aFGF, about 10 ng/ml FGF4 and about 25 ng/ml FGF8b.
5. The method of claim 1 , wherein the cells are cultured in step (d) with about 20 ng/ml HGF and about 100 ng/ml Follistatin.
6. A method for producing cells with a hepatic stellate phenotype and cells with a hepatic sinusoidal endothelial phenotype, comprising:
(a) culturing pluripotent cells with about 50 ng/ml Wnt3a and about 100 ng/ml ActivinA;
(b) then culturing the cells of step (a) with about 10 ng/ml bFGF and about 50 ng/ml BMP4;
(c) then culturing the cells of step (b) with about 50 ng/ml aFGF, about 10 ng/ml FGF4 and about 25 ng/ml FGF8b;
(d) then culturing the cells of step (c) with about 20 ng/ml HGF and about 100 ng/ml Follistatin; and
(e) isolating hepatic stellate cells and/or hepatic endothelial sinusoidal cells produced by the differentiation protocol.
7. The method of claim 1 , wherein the steps are for at least four days each.
8. The method of claim 1 , wherein step (a) is about six days, step (b) is about four days, step (c) is about four days, and step (d) is about seven to fourteen days.
9. The method of any of claims 1 - 8 , wherein the cells that are contacted with Wnt3A and Activin A are mammalian.
10. The method of claim 9 , wherein the cells that are contacted with Wnt3A and Activin A are human, mouse, or rat.
11. The method of claim 10 , wherein the cells that are contacted with Wnt3A and Activin A are embryonic stem cells or cells that are not embryonic stem cells, embryonic germ cells or germ cells, and can differentiate into at least one cell type of each of the endodermal, ectodermal and mesodermal embryonic lineages.
12. The method of claim 11 wherein the cells are not embryonic germ cells, embryonic stem cells or germ cells, and can differentiate into at least one cell type of each of the endodermal, ectodermal and mesodermal embryonic lineages.
13. The method of claim 1 where isolation of hepatic stellate cells in step (e) is carried out using one or more markers selected from the group consisting of Vitamin A + , PPARg + , GFAP + , GPR91 + , ALCAM, CRBP high , p75NTR + , COL1a1 high , and TIMP-1 low .
14. The method of claim 1 where isolation of liver sinusoidal endothelial cells in step (e) is carried out using one or more markers selected from the group consisting of CD32b + , Stab-1 + , Stab-2 + , L-SIGN + , and MRC1 + .
15. The method of claim 12 wherein the non-embryonic stem, non-germ, non-embryonic germ cells are derived from bone marrow.